ProPhase Labs Files 8-K/A Amendment
Ticker: PRPH · Form: 8-K/A · Filed: Dec 18, 2025 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | 8-K/A |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, corporate-governance, filing
Related Tickers: PRPH
TL;DR
ProPhase Labs (PRPH) filed an 8-K/A amendment on 12/18, updating corporate docs. Watch for details.
AI Summary
ProPhase Labs, Inc. filed an amendment (8-K/A) on December 18, 2025, to its report originally dated December 10, 2025. This amendment primarily concerns changes to its Articles of Incorporation or Bylaws, other events, and financial statements/exhibits. The company, formerly known as QUIGLEY CORP, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates ProPhase Labs is making formal changes to its corporate structure or governance, which could impact its operational framework and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not appear to disclose new material adverse information.
Key Numbers
- 000-21617 — SEC File Number (Identifies the company's filing with the SEC.)
- 23-2577138 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- ProPhase Labs, Inc. (company) — Filer
- QUIGLEY CORP (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- December 10, 2025 (date) — Earliest event reported date
- December 18, 2025 (date) — Filing Date
FAQ
What specific changes were made to the Articles of Incorporation or Bylaws?
The filing is an amendment (8-K/A) and indicates changes to these documents, but the specific details of the changes are not provided in the provided text snippet.
What are the 'Other Events' mentioned in the filing?
The filing indicates 'Other Events' are part of the amendment, but the nature of these events is not detailed in the provided text.
What is the significance of the 'Financial Statements and Exhibits' being amended?
This suggests that financial information or supporting documents previously filed are being updated or corrected as part of this amendment.
When was ProPhase Labs, Inc. formerly known as QUIGLEY CORP?
The date of the name change from QUIGLEY CORP to ProPhase Labs, Inc. was March 28, 1993.
What is the primary business of ProPhase Labs, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code 2834 indicates the company operates in Pharmaceutical Preparations.
Filing Stats: 1,134 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2025-12-18 13:30:45
Key Financial Figures
- $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Markets Indi
Filing Documents
- form8-ka.htm (8-K/A) — 44KB
- ex1.htm (EX-1) — 3KB
- ex1_001.jpg (GRAPHIC) — 2342KB
- ex1_002.jpg (GRAPHIC) — 1497KB
- 0001493152-25-028317.txt ( ) — 5501KB
- prhp-20251210.xsd (EX-101.SCH) — 3KB
- prhp-20251210_lab.xml (EX-101.LAB) — 33KB
- prhp-20251210_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ProPhase Labs, Inc. By: /s/ Ted Karkus Ted Karkus Chairman of the Board and Chief Executive Officer Date: Thursday, December 18, 2025